Clinical Trial Update: BVD-523 Plus Nab-paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Cancer [Phase 1]

View source ↗

Summary

Phase 1 trial update of BVD-523 with nab-paclitaxel and gemcitabine in metastatic pancreatic cancer; study terminated with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Cancer

Drugs mentioned

• BVD-523
• Gemcitabine (Gemcitabine)
• Nab-paclitaxel (paclitaxel protein-bound)

Snippet

Sponsor: Washington University School of Medicine | Conditions: Pancreatic Cancer, Cancer of Pancreas | Phase 1 | Status: TERMINATED | Results posted: 2020-05-01